Regional differences in precipitating factors of hospitalization for acute heart failure: insights from the REPORT-HF registry.


Journal

European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595

Informations de publication

Date de publication:
04 2022
Historique:
revised: 05 01 2022
received: 07 10 2021
accepted: 14 01 2022
pubmed: 23 1 2022
medline: 18 5 2022
entrez: 22 1 2022
Statut: ppublish

Résumé

Few prior studies have investigated differences in precipitants leading to hospitalizations for acute heart failure (AHF) in a cohort with global representation. We analysed the prevalence of precipitants and their association with outcomes in 18 553 patients hospitalized for AHF in REPORT-HF (prospective international REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure) according to left ventricular ejection fraction subtype (reduced [HFrEF] and preserved ejection fraction [HFpEF]) and presentation (new-onset vs. decompensated chronic heart failure [DCHF]). Patients were enrolled from 358 centres in 44 countries stratified according to Latin America, North America, Western Europe, Eastern Europe, Eastern Mediterranean and Africa, Southeast Asia, and Western Pacific. Precipitants were pre-with mutually exclusive categories and selected according to the local investigator's discretion. Outcomes included in-hospital and 1-year mortality. The median age was 67 (interquartile range 57-77) years, and 39% were women. Acute coronary syndrome (ACS) was the most common precipitant in patients with new-onset heart failure in all regions except for North America and Western Europe, where uncontrolled hypertension and arrhythmia, respectively, were the most common precipitants, independent of confounders. In patients with DCHF, non-adherence to diet/medication was the most common precipitant regardless of region. Uncontrolled hypertension was a more likely precipitant in HFpEF, non-adherence to diet/medication, and ACS were more likely precipitants in HFrEF. Patients admitted due to worsening renal function had the worst in-hospital (5%) and 1-year post-discharge (30%) mortality rates, regardless of region, heart failure subtype and admission type (p Data on global differences in precipitants for AHF highlight potential regional differences in targets for preventing hospitalization for AHF and identifying those at highest risk for early mortality.

Identifiants

pubmed: 35064730
doi: 10.1002/ejhf.2431
pmc: PMC9106888
mid: NIHMS1772282
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

645-652

Subventions

Organisme : NHLBI NIH HHS
ID : R61 HL155810
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2022 European Society of Cardiology.

Références

JAMA Cardiol. 2020 Apr 1;5(4):401-410
pubmed: 31913404
Eur J Heart Fail. 2015 May;17(5):527-33
pubmed: 25754836
Eur J Heart Fail. 2017 Oct;19(10):1242-1254
pubmed: 28463462
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
Lancet Glob Health. 2019 Jun;7(6):e748-e760
pubmed: 31028013
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Eur J Heart Fail. 2018 Feb;20(2):295-303
pubmed: 28872259
Lancet. 2021 Jun 19;397(10292):2337-2360
pubmed: 34051883
Lancet. 2021 Sep 11;398(10304):957-980
pubmed: 34450083
Am Heart J. 2022 Jan;243:11-14
pubmed: 34516969
Medicine (Baltimore). 2015 Dec;94(52):e2330
pubmed: 26717369
Arch Intern Med. 2001 Oct 22;161(19):2337-42
pubmed: 11606149
JACC Heart Fail. 2016 Jun;4(6):464-72
pubmed: 27256749
Am Heart J. 2009 Oct;158(4):644-52
pubmed: 19781426
Am J Cardiol. 1996 Aug 1;78(3):354-7
pubmed: 8759821
Eur J Heart Fail. 2017 Feb;19(2):201-208
pubmed: 27790819
Arch Intern Med. 2008 Apr 28;168(8):847-54
pubmed: 18443260
Eur J Heart Fail. 2017 Dec;19(12):1574-1585
pubmed: 28386917
Circulation. 2019 Jan 29;139(5):575-586
pubmed: 30586760
Lancet Glob Health. 2020 Mar;8(3):e411-e422
pubmed: 32087174
Eur J Intern Med. 2020 Jan;71:62-69
pubmed: 31708361
Arch Intern Med. 1988 Sep;148(9):2013-6
pubmed: 3046541
Heart. 1998 Nov;80(5):437-41
pubmed: 9930040
Am J Public Health. 1997 Apr;87(4):643-8
pubmed: 9146445

Auteurs

Jasper Tromp (J)

Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore.
Duke-NUS Medical School, Singapore.

Joost C Beusekamp (JC)

University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Wouter Ouwerkerk (W)

National Heart Centre Singapore, Singapore.
Department of Dermatology, Amsterdam UMC, University of Amsterdam, Amsterdam Infection & Immunity Institute, Amsterdam, The Netherlands.

Peter van der Meer (P)

University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

John G F Cleland (JGF)

Robertson Centre for Biostatistics and Clinical Trials, Institute of Health & Well-Being, University of Glasgow and National Heart & Lung Institute, Imperial College, London, UK.

Christiane E Angermann (CE)

Comprehensive Heart Failure Centre, University Hospital and University of Würzburg, Würzburg, Germany.

Ulf Dahlstrom (U)

Department of Cardiology and Department of Health, Medicine and Caring Sciences, Linkoping University, Linkoping, Sweden.

Georg Ertl (G)

Comprehensive Heart Failure Centre, University Hospital and University of Würzburg, Würzburg, Germany.

Mahmoud Hassanein (M)

Alexandria University, Faculty of Medicine, Cardiology Department Alexandria, Egypt.

Sergio V Perrone (SV)

El Cruce Hospital by Florencio Varela, Lezica Cardiovascular Institute, Sanctuary of the Trinidad Miter, Buenos Aires, Argentina.

Mathieu Ghadanfar (M)

M-Ghadanfar Consulting (Life Sciences), Basel, Switzerland.

Anja Schweizer (A)

Novartis Pharma AG, Basel, Switzerland.

Achim Obergfell (A)

Novartis Pharma AG, Basel, Switzerland.

Gerasimos Filippatos (G)

University of Cyprus, School of Medicine & National and Kapodistrian University of Athens, School of Medicine, Department of Cardiology, Attikon University Hospital, Athens, Greece.

Kenneth Dickstein (K)

University of Bergen, Stavanger University Hospital, Norway.

Sean P Collins (SP)

Vanderbilt University Medical Center and Veterans Affairs Tennessee Valley Healthcare System, Geriatric Research, Education and Clinical Center (GRECC), Department of Emergency Medicine, Nashville, Tennessee, USA.

Carolyn S P Lam (CSP)

Duke-NUS Medical School, Singapore.
University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
National Heart Centre Singapore, Singapore.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH